Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
37 hedge funds and large institutions have $1.73M invested in Carisma Therapeutics in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 7 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.11% less ownership
Funds ownership: 13.47% → 13.36% (-0.11%)
10% less funds holding
Funds holding: 41 → 37 (-4)
27% less capital invested
Capital invested by funds: $2.35M → $1.73M (-$625K)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Universal-Beteiligungs- und Servicegesellschaft
Frankfurt Am Main,
Germany
|
+$88.6K |
| 2 |
Renaissance Technologies
New York
|
+$9.88K |
| 3 |
SG
StoneX Group
New York
|
+$4.75K |
| 4 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
+$4.43K |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$291 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$50.3K |
| 2 |
HF
HRT Financial
New York
|
-$15K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$9.4K |
| 5 |
Goldman Sachs
New York
|
-$8.95K |
CARM Hedge Fund Activity: Q1 2025 in Review
37 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q1 2025, worth a combined $1.73M — down 27% from $2.35M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CARM and 3 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was Universal-Beteiligungs- und Servicegesellschaft, opening a new position worth an estimated $88.6K. The largest seller was Millennium Management, exiting entirely with an estimated $50.3K sold.
- 37 institutional investors held Carisma Therapeutics (CARM) as of Q1 2025, down from 41 in Q4 2024.
- Funds reported $1.73M of Carisma Therapeutics stock for Q1 2025, down 27% quarter-over-quarter.
- 3 funds opened new Carisma Therapeutics positions in Q1 2025 and 7 closed out, a net change of -4 holders.
- The largest Carisma Therapeutics buyer in Q1 2025 was Universal-Beteiligungs- und Servicegesellschaft, an estimated $88.6K added.
- The largest Carisma Therapeutics seller in Q1 2025 was Millennium Management, an estimated $50.3K sold.
Based on aggregated 13F filings for Q1 2025.